Thoratec Downplays Threats From Competing HeartWare Pump
This article was originally published in The Gray Sheet
Thoratec’s virtual monopoly in the LVAD market is about to end with the anticipated launch of HeartWare’s system this month or next, but executives are not displaying major concern.
You may also be interested in...
“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.
CMS does not currently have a national coverage determination process open on ventricular assist devices for heart failure, though the agency may open a new one, an agency official said.
Benefits of HeartWare system, as well as the prospect of adding a competitive device to a market currently dominated by a single product, overshadow uncertainties from missing data, panelists vote.